Relugolix was specifically compared to leuprolide, an injectable GnRH agonist commonly used to treat prostate cancer, in both their castration efficacy and cardiovascular risk in the HERO trial [79]. This evidence concerns the gene GNRH1 and Familial prostate cancer.